Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program.
We evaluated the visual outcome of a cohort of children with neurofibromatosis type 1 (NF1) and optic pathway glioma (OPG) treated according to standardized therapeutic guidelines. The study population consisted of all consecutive patients with NF1 and OPG referred to a specialized pediatric neuro-oncology program between 1994 and 2004. Treatment was instituted only in cases of progressive disease or clinical deterioration. Treatment modalities were chemotherapy (based on vincristine/carboplatin) for children younger than 5 years and radiotherapy for all others. Ten boys and 10 girls (seven with a positive family history) entered the trial (median age at diagnosis of OPG, 29 months). At a median follow-up time of 78 months, seven patients had been treated with chemotherapy only, four with radiotherapy, and four with chemotherapy plus radiotherapy. Five patients were observed only. Currently, 18 are alive and two have died. Eight patients were treated for progressive visual loss in the face of stable disease, five for tumor volume increase without visual deterioration, and two for symptomatic tumor volume increase. At referral, six children had a visual acuity (VA) of < 30% in both eyes; eight children had 100% VA bilaterally. At referral, the visual field (VF) could be assessed in three children: One had VF loss in both eyes, one had VF loss in one eye, and one had normal VF. At last follow-up, eight children had VA < 20% in both eyes; only two children had 100% VA in both eyes. Among 11 children who had some visual function, three had VF loss in one eye and three in both eyes, and five had an intact VF. Contrast and color sensitivity were abnormal in seven and six patients, respectively. Thirteen children fell into the WHO hypovision category. In summary, among the 15 children treated, one had a definitive and two a mild improvement in VA. In conclusion, the visual outcome of this selected cohort of NF1 patients with OPG is unsatisfactory. A critical reappraisal of the therapeutic strategy adopted is needed.
Dalla Via
Paola
P
Department of Pediatrics, University Hospital of Padua, Via Giustiniani 3, 35128 Padua, Italy.
Opocher
Enrico
E
Pinello
Maria Luisa
ML
Calderone
Milena
M
Viscardi
Elisabetta
E
Clementi
Maurizio
M
Battistella
Pier Antonio
PA
Laverda
Anna Maria
AM
Da Dalt
Liviana
L
Perilongo
Giorgio
G
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D015350:Contrast Sensitivity / Q000187:drug effects / Q000528:radiation effects; D005074:Evoked Potentials, Visual; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009456:Neurofibromatosis 1 / Q000150:complications / Q000628:therapy*; D020339:Optic Nerve Glioma / Q000150:complications / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014786:Vision Disorders / Q000209:etiology*; D014794:Visual Fields / Q000187:drug effects / Q000528:radiation effects
D014750:Vincristine; D016190:Carboplatin
Pediatrics. 2000 Mar;105(3 Pt 1):608-14
10699117
Klin Padiatr. 2004 Nov-Dec;216(6):331-42
15565548
J Neuroophthalmol. 2001 Mar;21(1):1-7
11315972
J Clin Oncol. 2002 Oct 15;20(20):4209-16
12377964
J Child Neurol. 2002 Aug;17(8):630-7; discussion 646-51
12403562
Pediatr Neurol. 2003 Apr;28(4):262-70
12849878
Am J Med Genet A. 2003 Oct 1;122A(2):95-9
12955759
Strahlenther Onkol. 2003 Sep;179(9):585-97
14628124
J Clin Oncol. 2003 Dec 15;21(24):4572-8
14673044
Ophthalmology. 2004 Mar;111(3):568-77
15019338
Cancer. 1995 Feb 15;75(4):1051-9
7842408
J Neurosurg. 1995 Oct;83(4):583-9
7674005
J Pediatr. 1995 Nov;127(5):718-22
7472822
J Neurooncol. 1996 May-Jun;28(2-3):167-83
8832460
Ann Neurol. 1997 Feb;41(2):143-9
9029062
AMA Arch Neurol Psychiatry. 1958 Jun;79(6):607-21
13532071
Am J Ophthalmol. 2001 Apr;131(4):442-5
11292406